title: EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?
authors.affiliation: Department of Oncology and Radiotherapy, Medical University of Gdańsk, 80 211 Gdańsk, Poland. jjassem@gumed.edu.pl
authors.forename: Jacek
authors.initials: J
authors.lastname: Jassem
authors.forename: Rafał
authors.initials: R
authors.lastname: Dziadziuszko
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000077143:Docetaxel; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D043823:Taxoids; D000077143:Docetaxel; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors